Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 22, Issue 5, Pages 609-619
Publisher
Elsevier BV
Online
2021-04-10
DOI
10.1016/s1470-2045(21)00056-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
- (2020) Nadeem R. Abu-Rustum et al. Journal of the National Comprehensive Cancer Network
- Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
- (2020) Chunyan Lan et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Joint ENGOT and GOG Foundation requirements for trials with industry partners
- (2019) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
- (2016) Stergios Boussios et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
- (2015) Ryo Kitagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
- (2015) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
- (2014) Johanna Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
- (2011) Emiliano Cocco et al. BMC CANCER
- Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
- (2009) D. Lorusso et al. ANNALS OF ONCOLOGY
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
- (2008) David Scott Miller et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now